Updated Phase II LEGEND data in heavily pretreated BCG-unresponsive non-muscle-invasive Bladder Cancer showed enGene’s detalimogene voraplasmid (EG-70) achieved a 54% complete response rate at any time and a 43% complete response rate at 6 months, well below investor expectations and prior benchmarks in the field. The interim analysis, based on about 125 patients and set to be presented at AUA, triggered an roughly 80% plunge in enGene shares Thursday.

Why It Matters To Oncology

• Detalimogene is competing in a crowded BCG-unresponsive NMIBC space where durability — not just initial CR — is emerging as the key differentiator for regulators, clinicians, and drug developers.

• UBS had flagged a 6-month CR of 61% to 62% as clinically meaningful, versus the 43% reported here, with comparator benchmarks around 59% to 63% for CG Oncology’s cretostimogene grenadenorepvec and J&J’s TAR-200.

• Still, the dataset included a low 3.2% progression rate to muscle-invasive or more advanced disease, which may remain relevant in assessing overall clinical utility.

The Financials

• enGene shares fell about 80% after the update, reflecting how sharply markets are discounting weaker-than-expected durability in late-stage oncology programs.

• The company had previously said it planned a regulatory filing by the end of 2026, but this readout may complicate its positioning with investors and potentially with regulators.

• For drug discovery teams, the reaction is a reminder that in NMIBC, commercial value is tightly linked to sustained response data against a fast-moving competitive set.

What They're Saying

• CEO Ron Cooper said, “While durability outcomes to date are not what we hoped, these data are preliminary.”

• Management emphasized the “totality” of the dataset, noting some patients remain in follow-up and that additional complete responses could still emerge at later assessments.

• The company also pointed to an estimated 25% of responders maintaining response at 12 months and a median duration of response of 37.3 months.

What's Next

• Full results from the Phase II LEGEND study are scheduled for presentation next week at the American Urological Association meeting.

• Clinicians and oncology developers will be watching for more mature durability data, especially 12-month response outcomes and subgroup detail in carcinoma in situ with or without papillary disease.

• Safety will also stay in focus: 55% had treatment-related adverse events, mostly mild, with grade 3 or higher events in 4.8% and treatment discontinuation or interruption in 2.4%.